VB4-845 Licensing Opportunity VIVENTIA Bio Inc. VB4-845

First Page		Document Content
Date: 2013-03-14 08:28:18 Bladder cancer Prostate cancer Antibody-drug conjugate Medicine Oncology Epithelial cell adhesion molecule		VB4-845 Licensing Opportunity VIVENTIA Bio Inc. VB4-845 Add to Reading List Source URL: www.viventia.com Download Document from Source Website File Size: 298,40 KB Share Document on Facebook

	Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at DocID: 1vlFR - View Document
	Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at DocID: 1ugjL - View Document
	OUTSOURCING Highly potent market growth Highly potent small-molecule and biologic drugs are typically considered to be those APIs that have an occupational DocID: 1pQiB - View Document
	FAKULTÄT FÜR CHEMIE Einladung zum Vortrag von __________________________________________________________________________ Dr. Gonçalo Bernardes DocID: 1pJ1J - View Document
	Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 217 Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2Breast Cancer DocID: 1mOZw - View Document